title: Differentiating genomics companies.
abstract: As the value of raw sequence data diminishes, genomics companies are evolving new competencies as providers of information, therapeutic products, or novel technology.
authors.affiliation: Prelude Technology Investments, Cambridge CB4 5PJ, UK. rob.james@prelude-technology.co.uk
authors.forename: R
authors.initials: R
authors.lastname: James
mesh_terms: D001709:Biotechnology / Q000191:economics*; D019295:Computational Biology / Q000191:economics*; D004345:Drug Industry / Q000191:economics*; D015894:Genome, Human; D006801:Humans; D007449:Investments / Q000639:trends*